Brain Implant Startup Paradromics Gets Green Light for Human Trial in US.
Paradromics, an Austin-based company developing a brain implant device to restore speech in people with severe motor impairment, has received approval from the FDA to conduct its first human trial. The Connexus implant, consisting of 421 microwire electrodes that record individual neurons, aims to decode signals associated with speaking.
According to Paradromics' CEO and founder Matt Angle, a two-person study is planned for early next year. Participants will attempt to say words aloud while the device records brain activity patterns related to speech. The data will then be used to generate a synthesized voice clone.
Angle emphasizes that this technology does not "read thoughts" but rather decodes signals from specific neurons in the brain's motor cortex associated with movement and speaking.
In a parallel experiment, Paradromics briefly implanted its device in someone already undergoing brain surgery earlier this year. The implant remained in place for just 10 minutes without being used to restore speech.
While Neuralink has also made strides in developing brain-computer interfaces (BCIs), Paradromics is focusing on high-bandwidth technology that can transfer large amounts of neural data between the brain and a computer. Recent preprints have shown promising results, including achieving 200 bits-per-second data transfer rates.
Industry colleagues are optimistic about Paradromics' progress, citing improved performance with industrial-scale BCIs comparable to iPhones improving over time.
Paradromics, an Austin-based company developing a brain implant device to restore speech in people with severe motor impairment, has received approval from the FDA to conduct its first human trial. The Connexus implant, consisting of 421 microwire electrodes that record individual neurons, aims to decode signals associated with speaking.
According to Paradromics' CEO and founder Matt Angle, a two-person study is planned for early next year. Participants will attempt to say words aloud while the device records brain activity patterns related to speech. The data will then be used to generate a synthesized voice clone.
Angle emphasizes that this technology does not "read thoughts" but rather decodes signals from specific neurons in the brain's motor cortex associated with movement and speaking.
In a parallel experiment, Paradromics briefly implanted its device in someone already undergoing brain surgery earlier this year. The implant remained in place for just 10 minutes without being used to restore speech.
While Neuralink has also made strides in developing brain-computer interfaces (BCIs), Paradromics is focusing on high-bandwidth technology that can transfer large amounts of neural data between the brain and a computer. Recent preprints have shown promising results, including achieving 200 bits-per-second data transfer rates.
Industry colleagues are optimistic about Paradromics' progress, citing improved performance with industrial-scale BCIs comparable to iPhones improving over time.